Alberti W, Quack G, Krischke W, Lommatzsch A, Huyer C, Krahl H
Klinik für Strahlentherapie und Nuklearmedizin, Alfried-Krupp-Krankenhaus, Essen.
Dtsch Med Wochenschr. 1995 Jul 14;120(28-29):983-9. doi: 10.1055/s-2008-1055435.
Clinically relevant heterotopic bone formation (HBF) following total hip arthroplasty (THA) occurs in about one third of all high risk patients. HBF can reduce the functional result of surgery by pain and limited range of motion. The experience with patients treated with postoperative radiation therapy after THA with or without removal of HBF is reported.
Between November 1986 und June 1993, postoperative irradiation was performed on 238 hips of 216 patients (117 men, 99 women, median age 66 years, range 38-86 years) with defined risk factors using 10 Gy in 5 fractions (n = 176) or 7 Gy in one fraction (n = 62) with a cobalt unit. In general, irradiation was performed during the first four postoperative days after primary THA alone in 182 hips or removal of HTB in 56 hips with (n = 28) or without (n = 28) revision surgery. Risk factors for HBF were preexisting ipsi- or contralateral HBF in 105 hips (group 1) or hypertrophic osteoarthritis, previous operative procedures of the hip and others in 134 hips (group 2). After a follow-up of at least 6 months patients were examined and radiographs of the hip were performed to classify HBF.
New or progressive ossifications had developed in the interval in 15 of 104 hips of group 1 (14.4%), compared with 19 of 134 hips in group 2 (14.2%). Clinically significant new HBF (grade 3 or 4) occurred in none of group 2, and in 3 hips of group 1 (2.9%). After radiation with 10 Gy HBF of all grades occurred in 23 of 176 hips (13.1%), and in nine of 62 hips after 7 Gy (14.5%). The lowest number of treatment failures was found in patients irradiated during the first 4 postoperative days.
These results demonstrate that immediate postoperative radiation is efficacious for prevention of clinically relevant HBF following THA and removal of HBF.
全髋关节置换术(THA)后临床上相关的异位骨形成(HBF)发生在约三分之一的所有高风险患者中。HBF可通过疼痛和活动范围受限降低手术的功能效果。本文报告了THA后接受或未接受HBF切除的患者术后放疗的经验。
1986年11月至1993年6月期间,对216例患者(117例男性,99例女性,中位年龄66岁,范围38 - 86岁)的238髋进行术后放疗,这些患者具有明确的风险因素,采用钴源装置分5次给予10 Gy(n = 176)或单次给予7 Gy(n = 62)。一般来说,182髋仅在初次THA术后的前四天进行放疗,56髋在有(n = 28)或无(n = 28)翻修手术的情况下切除HTB后进行放疗。HBF的风险因素为105髋存在同侧或对侧既往HBF(第1组),或134髋存在肥厚性骨关节炎、既往髋关节手术及其他情况(第2组)。随访至少6个月后检查患者并拍摄髋关节X线片以对HBF进行分类。
第1组104髋中有15髋(14.4%)在随访期间出现新的或进展性骨化,第2组134髋中有19髋(14.2%)出现。第2组无临床上显著的新HBF(3级或4级)发生,第1组有3髋(2.9%)发生。10 Gy放疗后,176髋中有23髋(13.1%)出现各级HBF,7 Gy放疗后62髋中有9髋(14.5%)出现。术后前4天接受放疗的患者治疗失败的数量最少。
这些结果表明,术后立即放疗对预防THA后临床上相关的HBF及切除HBF有效。